Mindfulness-Based Cognitive Therapy & MBSR: Independent Evidence

Table of contents

• Evidence summary
• What mindfulness-based therapy is
• How it works
• What works and what does not
• Benefits by claim
• Risks and adverse effects
• Combining it with medicines and other therapies
• Who it may not suit
• How it is delivered and what a course looks like
• Follow the money: who sells it and who funded the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator or government body; 2 = academic or Cochrane team with no declared commercial funding for the work; 3 = independent authors analysing mostly manufacturer-run trials, or minor declared industry ties; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D. For a therapy, we treat course developers, paid trainers and directors of mindfulness training centres as the nearest equivalent of a manufacturer (tier 3), and app companies as tier 4. Our sources cluster heavily in the UK and US, and the UK work is concentrated in a small network of Oxford, Exeter and Cambridge groups.

What mindfulness-based therapy is

"Mindfulness" means paying attention to the present moment, including thoughts, feelings and body sensations, and learning to see thoughts as "mental events" rather than facts (NHS: Mindfulness). The term covers very different things, and the evidence for one does not automatically transfer to another.

• Mindfulness-based stress reduction (MBSR): developed by Jon Kabat-Zinn at the University of Massachusetts medical centre in 1979 (UMass Memorial Health). It is an 8-week group course of meditation, gentle movement and body awareness, originally for people with chronic illness and pain. It is not designed around any one diagnosis.
• Mindfulness-based cognitive therapy (MBCT): developed by Zindel Segal, John Teasdale and Mark Williams. It grew out of MBSR and adds techniques from cognitive behavioural therapy (CBT) (UMass MBCT page). It was built specifically to help people who have recovered from depression spot early warning signs and step out of spirals of negative thinking (Teasdale et al. 2000).
• Adapted courses: versions for the general public (such as MBCT for Life), workplaces, universities and schools. These are newer and less tested.
• Apps and self-guided meditation: unguided recordings and programmes, such as Headspace and Calm. These are consumer products, not therapy, and are reviewed separately below.
• Other meditation traditions: Transcendental Meditation and religious practices have their own research, which we do not cover here except where reviews pooled them.

Status by country. Mindfulness courses are not licensed like medicines, and we found no statutory regulation of mindfulness teachers in the UK or US sources we reviewed. In England, MBCT is one of the therapies listed by NHS Talking Therapies for anxiety and depression, which people can self-refer to (NHS: Talking therapies). In the US, MBSR is generally not covered by health insurance; the Veterans Health Administration is the exception. A Brown University team reports that Singapore, Germany and Switzerland cover it under some plans (Brown School of Public Health, 2024).

How it works

The theory behind MBCT is that people who have been depressed before can be pulled back into depression when a dip in mood reactivates old patterns of negative thinking. MBCT trains them to notice this early and "disengage" from those thoughts (Teasdale et al. 2000). NICE describes the focus as noticing thoughts, feelings and body sensations "rather than on changing them" (NICE NG222, table 1).

What has been shown in humans:

• A meta-analysis of mediation studies found strong, consistent evidence that MBCT and MBSR reduce cognitive and emotional reactivity, and moderate evidence that changes in mindfulness, rumination (brooding) and worry help explain the benefit. The authors warned that most studies had methodological weaknesses that "preclude robust conclusions" (Gu et al. 2015).
• A Wellcome-supported review of 23 MBCT studies found that 12 linked changes in mindfulness, rumination, worry, self-compassion or "meta-awareness" to outcomes, but said more rigorous designs were needed to prove cause and effect (van der Velden et al. 2015).

What is not proven: claims that mindfulness "rewires" or "grows" the brain go well beyond the data. A group of 15 meditation and mindfulness researchers warned that misinformation and poor methods "may lead public consumers to be harmed, misled, and disappointed", and called for caution in interpreting brain-imaging studies (Van Dam et al. 2018). There are also non-specific ingredients that any group course provides: a weekly routine, a supportive group, and a trained person paying attention. This may be one reason why mindfulness looks better against no treatment than against other active treatments (Goldberg et al. 2018).

What works and what does not

Benefits by claim

Preventing depression from coming back

This is MBCT's original purpose and its strongest evidence. The first large trial randomised 145 people who had recovered from recurrent depression to usual care with or without MBCT. Over 60 weeks, MBCT reduced relapse in those with 3 or more previous episodes (77% of the sample) but not in those with only 2 (Teasdale et al. 2000).

The best summary is an individual-patient-data meta-analysis, which re-analyses each participant's raw data rather than published averages. Across 9 trials and 1,258 patients (75% women, average age 47), MBCT cut the risk of relapse within 60 weeks compared with no MBCT (HR 0.69, 95% CI 0.58 to 0.82) and compared with other active treatments, including antidepressants (HR 0.79, 0.64 to 0.97). People with more leftover symptoms at the start seemed to gain more. Age, sex, education and number of past episodes did not change the effect (Kuyken et al. 2016).

What a hazard ratio of 0.69 means: at any point during follow-up, people offered MBCT were about 31% less likely to relapse than those not offered it. It does not mean 31% of people avoid depression. Many people in both groups still relapsed.

MBCT versus staying on antidepressants

The PREVENT trial was designed to test whether MBCT, combined with support to taper antidepressants, beats staying on them. It recruited 424 adults with 3 or more past episodes from 95 UK general practices. Over 24 months, 94 of 212 (44%) relapsed in the MBCT group and 100 of 212 (47%) on maintenance antidepressants (HR 0.89, 95% CI 0.67 to 1.18; p = 0.43). Serious adverse events were evenly split, and none was attributed to either treatment (Kuyken et al., Lancet 2015).

Of those who attended at least 4 sessions, 71% stopped their antidepressant and 17% reduced it. The probability that MBCT was more cost-effective never rose above 52% (PREVENT full text). The honest reading is that MBCT and maintenance medication performed similarly. This is why NICE presents MBCT as a choice "for people who do not wish to continue on antidepressants", or alongside them (NICE NG222, 1.8.5).

Current depression

MBCT was not designed for people in the middle of a depressive episode, but it has been tested there. A meta-analysis of 13 trials (1,046 people) found it better than non-specific controls at the end of treatment (d = 0.71, 95% CI 0.47 to 0.96), with no difference from other active therapies (d = 0.002, 95% CI −0.43 to 0.44). Higher-quality studies showed smaller effects, and only two trials compared it with non-specific controls at follow-up (Goldberg et al. 2019).

NICE lists "group mindfulness and meditation" as one of eleven options for less severe depression, ranked seventh, after guided self-help, group and individual CBT, behavioural activation and group exercise. It does not appear among the options for more severe depression (NICE NG222, tables 1 and 2).

Anxiety

The largest head-to-head test is the TAME trial at three US academic centres. 276 adults with a primary diagnosis of generalised anxiety, social anxiety, panic disorder or agoraphobia (trial description) were randomised to an 8-week MBSR course or escitalopram, with escitalopram dosing as set by the trial protocol. In the 208 people analysed, clinician-rated severity fell by 1.35 points with MBSR and 1.43 with escitalopram. The difference (−0.07, 95% CI −0.38 to 0.23) fell inside the pre-set margin, so MBSR was judged non-inferior (Hoge et al. 2023).

Two caveats. First, 68 of the 276 people randomised were not in the main analysis, although an imputed analysis gave the same answer. Second, participants knew which treatment they had. A broader meta-analysis of 142 samples (12,005 people) with psychiatric disorders found mindfulness beat no treatment (d = 0.55) and specific active controls (d = 0.23), but did not differ from established evidence-based treatments (d = −0.004) (Goldberg et al. 2018). NICE's anxiety guideline recommends CBT, applied relaxation and medicines, and does not mention mindfulness (NICE CG113).

Everyday stress: workplaces and universities

A Cambridge team pooled 136 trials (11,605 adults in 29 countries) of in-person courses in non-clinical settings. Compared with no intervention, courses improved anxiety (SMD −0.56), depression (SMD −0.53), distress (SMD −0.45) and well-being (SMD 0.33). Against specific active comparisons (other interventions designed to help), there was no statistically significant evidence that mindfulness was better. Only the effect on distress survived when higher-risk trials were removed, and US-based trials reported smaller effects. Certainty was rated moderate to very low (Galante et al., PLOS Medicine 2021).

The same team then obtained raw data from 13 trials (2,371 participants). Courses reduced distress 1 to 6 months later (SMD −0.32, 95% CI −0.41 to −0.24), with high confidence and no sign that age, sex, education or starting distress changed the effect (Galante et al., Nature Mental Health 2023). The comparison was with passive controls, and participants were volunteers.

In a trial of 616 Cambridge students, an 8-week course reduced distress during exams. 37% of course participants scored above a clinical threshold, against 57% given usual support; about 6 students needed to be offered the course to prevent one case (Galante et al. 2018). NICE's workplace guideline advises employers to offer all employees mindfulness, yoga or meditation on an ongoing basis (NICE NG212, 1.6.4).

Schools and teenagers

MYRIAD, the largest trial of school mindfulness, randomised 84 UK secondary schools. Teachers trained to deliver 10 lessons were compared with normal social-emotional teaching. After 1 year there was no benefit on depression risk (SMD 0.005, 95% CI −0.05 to 0.06), social-emotional functioning or well-being (Kuyken et al. 2022). A follow-up analysis found slightly worse depression-risk and well-being scores in pupils already at risk. The difference was small and not clinically relevant, but the authors concluded the programme "may be contraindicated" for pupils with existing or emerging symptoms (Montero-Marin et al. 2022).

Blood pressure and heart health

A 2024 Cochrane review of 81 trials (6,971 people at risk of or with heart disease) found very little information on heart attacks, strokes or deaths. Against no intervention, mindfulness lowered systolic blood pressure by 6.62 mmHg on average, but the confidence interval ran from −13.15 to −0.1 and results were highly inconsistent (I² = 87%; low certainty). Against active comparators the effect was not clear (Rees et al., Cochrane 2024). The American Heart Association gave "other meditation techniques" (meaning not Transcendental Meditation) a Class III rating, the category for no proven benefit, based on the lowest level of evidence (Brook et al. 2013). NCCIH, citing a 2017 American Heart Association statement, says the specific effects of meditation on blood pressure "have not been determined" (NCCIH).

Chronic pain

In a US trial of 342 adults with chronic low back pain, MBSR and CBT, each given as 8 weekly 2-hour groups, both beat usual care. At 26 weeks, 60.5% of the MBSR group had meaningful improvement in function, against 44.1% with usual care (RR 1.37, 95% CI 1.06 to 1.77), and results held at 52 weeks. MBSR and CBT did not differ (Cherkin et al. 2016). Across 38 trials of pain, a RAND review found low-quality evidence of a small reduction in pain (Hilton et al. 2017). NCCIH cites a 2020 AHRQ report linking MBSR to short-term improvement in low back pain but not fibromyalgia pain (NCCIH).

Apps and self-guided meditation

A 2024 meta-analysis of 45 app trials found small benefits over control groups for depression (g = 0.24; about 14 people need to use an app for one to benefit) and anxiety (g = 0.28; about 11). Effects held in lower-risk-of-bias trials, but apps did not beat active therapeutic comparisons, and trials that paid participants showed larger effects on depression (Linardon et al. 2024). Apps are not equivalent to an 8-week teacher-led course, and most of the evidence above does not apply to them.

Risks and adverse effects

Mindfulness is often presented as harmless. The evidence says it is usually low-risk but not risk-free, and that harms have been under-measured. NCCIH notes that "few studies have examined these practices for potentially harmful effects" (NCCIH). The NHS says some people find mindfulness "can make them feel worse" (NHS).

Why harms are under-reported: Britton's team notes that, in earlier mindfulness trials, passive monitoring recorded serious adverse events in under 1% of participants, while direct questioning found far higher rates. They also cite earlier work in which researcher conflicts of interest predicted fewer adverse events being reported in the mindfulness arm (Britton et al. 2021, full text). A review led by MBCT researchers called for harm to be studied as carefully as in drug and psychotherapy research (Baer et al. 2019).

For balance: in the TAME anxiety trial, at least one study-related adverse event was reported by 15.4% of the MBSR group and 78.6% of the escitalopram group, and 8% of the escitalopram group but no one in the MBSR group stopped because of side effects (Hoge et al. 2023). In PREVENT, serious adverse events were similar in both groups and none was attributed to the treatments (PREVENT).

Combining it with medicines and other therapies

Mindfulness has no drug interactions in the pharmacological sense. The real risks come from changing other treatments around it.

• With antidepressants: NICE says people at higher risk of relapse can continue their antidepressant, switch to group CBT or MBCT if they do not want to continue medication, or do both (NICE NG222, 1.8.5). In PREVENT, trial guidance suggested starting any taper after about 6 weeks of the course, but each regimen was decided by the patient and their GP (PREVENT full text). Stopping antidepressants can cause withdrawal symptoms and should be planned with the prescriber.
• With other psychological therapy: PREVENT excluded people already in formal psychotherapy, so there is little trial evidence on doing both at once. Tell each therapist about the other.
• With trauma treatment: because traumatic re-experiencing is one of the commonest meditation-related effects (Goldberg et al. 2022), people in treatment for PTSD may want to discuss timing with their trauma therapist.

Who it may not suit

• People in a severe depressive episode: NICE notes group mindfulness "may be difficult for people experiencing intense or highly distressing thoughts, or who find focusing on the body difficult" (NICE NG222).
• People with only one or two past episodes of depression: the first major trial found no relapse benefit in people with 2 previous episodes (Teasdale et al. 2000).
• People with significant trauma or dissociation: childhood adversity raised the risk of adverse effects (Goldberg et al. 2022), and lasting harms were linked to hyperarousal and dissociation (Britton et al. 2021). The authors of the US survey called for more trauma-sensitive teaching.
• People with psychosis, bipolar disorder, active substance misuse or frequent self-injury: these groups were excluded from PREVENT, so the main evidence does not apply to them (PREVENT full text). Specialist advice is needed.
• Young teenagers in universal school programmes: the school version tested in MYRIAD did not help and may not suit pupils with emerging symptoms (Montero-Marin et al. 2022).
• People who cannot commit the time: courses require weekly sessions and daily home practice of up to an hour, including recordings between sessions (NICE NG222; UMass MBSR).

How it is delivered and what a course looks like

Getting it on the NHS

In England, adults registered with a GP can refer themselves to NHS Talking Therapies for anxiety and depression, and MBCT is one of the listed therapy types (NHS: Talking therapies). In practice, availability varies. A national NIHR-funded study of UK services found that access to MBCT "remains patchy" and often depends on local champions building services over many years (Rycroft-Malone et al. 2019). The Oxford Mindfulness Foundation, a charity, offers MBCT for depression in collaboration with the NHS Nottingham Centre for Mindfulness to UK residents registered with a GP (Oxford Mindfulness Foundation).

Private courses and cost

Private prices vary widely and we could not find a neutral survey of UK fees. As one documented example, UMass Memorial Health, where MBSR began, lists tuition of $650 for its 8-week MBSR or MBCT course (UMass tuition page). We found no statutory regulation of mindfulness teaching. If paying privately for therapy, the NHS advises choosing a practitioner registered with a professional body accredited by the Professional Standards Authority (NHS). NICE's description calls for at least one practitioner with therapy-specific training (NICE NG222), and established providers such as UMass include an initial one-to-one meeting with an instructor (UMass MBCT).

Follow the money: who sells it and who funded the evidence

Who sells mindfulness

• Health services and universities: NHS services, university mindfulness centres and hospital programmes. UMass Memorial Health, where MBSR began in 1979, sells courses and retreats (UMass).
• Charities and training organisations: the Oxford Mindfulness Foundation (registered charity 1122517) runs public courses, teacher training and an app (Oxford Mindfulness Foundation). Teacher training is itself a market: a co-author of the NHS implementation study directs a university centre "which delivers professional training for mindfulness-based teachers" (Rycroft-Malone 2019 disclosures).
• Books: MBCT's developers Teasdale, Williams and Segal receive royalties for books on MBCT (Kuyken 2016 disclosures).
• Apps: the largest commercial players are US venture-backed companies. Calm raised $75 million at a $2 billion valuation in December 2020, in a round led by Lightspeed Venture Partners, with Insight, TPG and Marc Benioff also investing, and reported 4 million paying members (TechCrunch). Headspace merged with the therapy platform Ginger in 2021 to form Headspace Health, valued at $3 billion (pharmaphorum). In September 2026 the digital health company Sword signed a definitive agreement to buy Headspace in an all-cash deal worth up to $300 million, roughly a tenth of that 2021 valuation, with the deal closed on 1 October 2026, according to Headspace's help centre (HLTH, 17 September 2026). We could not confirm whether the deal had completed by the date of this review.

Who funded the trials

• UK public and charitable money: PREVENT was funded by the NIHR Health Technology Assessment programme (project 08/56/01) (PREVENT). The individual-data meta-analysis was supported by Wellcome Trust grants, with NIHR and MRC support for some authors (Kuyken 2016). MYRIAD was funded by Wellcome (MYRIAD). The Galante reviews were funded by an NIHR fellowship (Galante 2023). The NIHR is funded by the Department of Health and Social Care (NIHR). Wellcome is an independent charitable foundation funded from an investment portfolio of £39.9 billion (Wellcome).
• US public money: NIH's NCCIH funded the back pain trial, the harms studies and the Goldberg meta-analyses (Cherkin 2016; Britton 2021; Goldberg 2022). The Goyal review was an AHRQ contract (Goyal 2014). The MBSR versus escitalopram trial was funded by PCORI, not the NIH (Hoge 2023). PCORI was authorised by Congress in 2010 (PCORI).
• Other funders: the RAND pain review was sponsored by a US Department of Defense centre (Hilton 2017). The study of intensive meditators received money from the Bial Foundation, which the authors described as "a commercial source", alongside an NIH grant (Lindahl 2017).

Researcher allegiance: when the developers test their own therapy

For a drug, the main conflict is a manufacturer funding its own trials. For mindfulness, the closer parallel is that many trials are run by people who developed the programme, direct training centres, write books or are paid to teach. These ties are declared, and they do not make the results wrong. But psychotherapy research has long shown that allegiance can shape design and reporting, so they deserve to be visible.

• In the key relapse meta-analysis, all authors except the statistician and one reviewer were investigators on the pooled trials. Disclosed roles included the founder and current director of the Oxford Mindfulness Centre, the directors of mindfulness centres in Nijmegen and Hong Kong, book royalties, and payment for MBCT training workshops. Two of them pass such fees on: one to the Oxford Mindfulness Foundation charity and one to Radboud University Medical Centre. Three authors gave evidence to the UK Mindfulness All-Party Parliamentary Group (Kuyken 2016 disclosures).
• We could not verify PREVENT author declarations from the record we reviewed (PREVENT declaration).
• That parliamentary group's 2015 "Mindful Nation UK" report urged more public access to qualified teachers. Its secretariat is provided by The Mindfulness Initiative, a policy and advocacy organisation (The Mindfulness Initiative).
• To the field's credit, some of the most important negative findings came from the same researchers. PREVENT did not show MBCT was better than medication, and MYRIAD, led by the Oxford Mindfulness Centre's director, reported a clear null result for schools (MYRIAD).

Publication and reporting bias

An unfunded Canadian-US analysis found that 87% of 124 published mindfulness therapy trials reported at least one positive result. Its abstract also reports about 66 positive trials expected at the effect size used, and 13 of 21 registrations (62%) still unpublished 30 months after completion (Coronado-Montoya et al. 2016). The Goldberg review of MBCT for current depression, by contrast, judged the impact of publication bias "minimal" (Goldberg 2019).

App companies and research

• A Calm app trial in 88 stressed college students reported moderate to large benefits against a wait-list. The paper's own disclosure says the lead author is Calm's Director of Science, a role taken up almost a year after the study's design, data collection and analysis (Huberty et al. 2019).
• A large NHS trial of Headspace in 2,182 health workers found small reductions in stress but no effect on burnout or sickness absence. Headspace funded the lead author's doctoral studentship, and co-authors had received Headspace research funding (Taylor et al. 2022).
• An independent meta-analysis whose authors declared no conflicts found the effects of apps were small and short term (Linardon 2024).

Documented integrity events

We found no regulatory warnings or enforcement actions concerning MBCT or MBSR courses in the sources we reviewed. We did not complete a search for consumer-protection actions against meditation-app companies, so none are reported here. The main documented integrity issues are scientific rather than legal: selective reporting, unpublished registered trials, and weak monitoring of harms, as set out above.

What this means: unlike most supplements and medicines we review, mindfulness research is mainly paid for with public and charitable money. The bias risk lies less in who pays and more in who runs the studies: a close-knit group of developers and trainers whose careers are tied to the therapy. Their best trials are rigorous and include honest null results. Independent reviews broadly confirm a modest benefit for relapse prevention, anxiety and stress, and find nothing to support the larger physical-health claims.

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• Depression relapse prevention
• Major depressive disorder
• Antidepressant withdrawal and dependence
• Generalised anxiety disorder
• Escitalopram: independent evidence
• Cognitive behavioural therapy (CBT)
• Behavioural activation for depression
• Trauma-focused therapy
• Occupational burnout
• Workplace mental health prevention
• Stress and physical health
• Exercise and social support for mental health

Frequently asked questions

Sources and funding notes

What we could not verify: the funding statement of the 2024 Cochrane review on meditation and heart disease (only the abstract record was accessible); Europe PMC lists only Brazil's CNPq for the Farias review. We could not open the NHS Talking Therapies manual (the NHS England site blocked automated access), so how often local services actually offer MBCT is based on the 2019 implementation study. We found no neutral source for typical UK private course fees; the Oxford Mindfulness Foundation's prices were not visible in its page text. Headspace's help centre reports the Sword purchase closed on 1 October 2026, while its own announcement says only "Fall 2026"; we found no citable valuation of Calm more recent than 2020; we did not complete a search for consumer-law actions against app companies. Note for readers of other summaries: the 2023 Galante individual-data meta-analysis was published in Nature Mental Health, while the 2021 Galante review in PLOS Medicine pooled published results; and the MBSR versus escitalopram trial was funded by PCORI, not the NIH.

1. NICE NG222. Depression in adults: treatment and management (2022) — UK guideline; Department of Health and Social Care.
2. NICE NG212. Mental wellbeing at work (2022) — UK guideline.
3. NICE CG113. Generalised anxiety disorder and panic disorder in adults — UK guideline; no mention of mindfulness.
4. NICE NG193. Chronic pain (primary and secondary) — UK guideline; recommends ACT or CBT for chronic primary pain.
5. NHS website. Mindfulness (reviewed 17 August 2026) — UK government health information.
6. NHS website. Talking therapies — UK government health information; self-referral and therapy types.
7. NCCIH. Meditation and mindfulness: effectiveness and safety — US government (NIH).
8. Goyal M et al. Meditation programs for psychological stress and well-being. JAMA Intern Med 2014 (full text) — US; AHRQ contract HHSA 290 2007 10061I; no conflicting affiliations.
9. Kuyken W et al. Efficacy of MBCT in prevention of depressive relapse: individual patient data meta-analysis. JAMA Psychiatry 2016 (full text) — UK/international; Wellcome, NIHR, MRC; extensive developer and trainer disclosures.
10. Kuyken W et al. MBCT vs maintenance antidepressants (PREVENT). Lancet 2015 (open-access full text) — UK; NIHR HTA 08/56/01; two authors co-directed the Mindfulness Network CIC.
11. Teasdale JD et al. Prevention of relapse/recurrence in major depression by MBCT. J Consult Clin Psychol 2000 — UK/Canada; trial by MBCT's developers; funded by NIMH (grant MH53457).
12. Goldberg SB et al. MBCT for current depressive symptoms: meta-analysis. Cogn Behav Ther 2019 — US; NCCIH P01 AT004952; one author founded a non-profit mindfulness organisation.
13. Goldberg SB et al. Mindfulness-based interventions for psychiatric disorders: meta-analysis. Clin Psychol Rev 2018 — US; NCCIH P01 AT004952; same disclosure.
14. Hoge EA et al. MBSR vs escitalopram for anxiety disorders (TAME). JAMA Psychiatry 2023 (full text) — US; PCORI CER-2017C1-6522; PCORI-funded (CER-2017C1-6522).
15. Hu H et al. Mindfulness meditation vs escitalopram: secondary analysis of TAME. JAMA Netw Open 2024 — US; PCORI; used for the trial's diagnostic entry criteria.
16. Galante J et al. Individual participant data meta-analysis of adult mindfulness-based programmes in non-clinical settings. Nature Mental Health 2023 (full text) — UK; Wellcome, MRC, NCCIH, NIMH and Department of Health grants; one author reports past pharma consultancy and speaker roles.
17. Galante J et al. Mindfulness-based programmes for mental health promotion in non-clinical settings. PLOS Medicine 2021 — UK; NIHR; no competing interests.
18. Galante J et al. Mindful Student Study. Lancet Public Health 2018 — UK; University of Cambridge and NIHR.
19. Kuyken W et al. MYRIAD cluster randomised trial. Evid Based Ment Health 2022 — UK; Wellcome; authors direct or directed the Oxford Mindfulness Centre and receive book royalties.
20. Montero-Marin J et al. School-based mindfulness: what works, for whom and how in MYRIAD. Evid Based Ment Health 2022 — UK; Wellcome; same disclosures.
21. Cherkin DC et al. MBSR vs CBT or usual care for chronic low back pain. JAMA 2016 — US; NCCIH R01 AT006226; conflicts not verified.
22. Hilton L et al. Mindfulness meditation for chronic pain. Ann Behav Med 2017 — US (RAND); Department of Defense centre contract; authors declare no conflicts.
23. Rees K et al. Meditation for the prevention of cardiovascular disease. Cochrane 2024 — UK; funding not verified; lead author an accredited mindfulness teacher (declared).
24. Brook RD et al. Alternative approaches to lowering blood pressure. AHA scientific statement, Hypertension 2013 — US professional society.
25. Jackson S et al. Mindfulness for smoking cessation. Cochrane 2022 — UK; Cancer Research UK, University College London, NIHR infrastructure funding; one author did research and consultancy for cessation-drug makers (Pfizer, Johnson & Johnson).
26. Linardon J et al. Efficacy of mindfulness apps: updated meta-analysis. Clin Psychol Rev 2024 — Australia/US; no conflicts declared.
27. Britton WB et al. Meditation-related adverse effects in mindfulness-based programs. Clin Psychol Sci 2021 (full text) — US; NCCIH K23 AT006328 and UH2/UH3 AT009145.
28. Farias M et al. Adverse events in meditation practices. Acta Psychiatr Scand 2020 — UK/Brazil; CNPq grant listed; full funding statement not seen.
29. Goldberg SB et al. Prevalence of meditation-related adverse effects in a US population sample. Psychother Res 2022 (full text) — US; NCCIH, NIMH, NIH and University of Wisconsin funds; one author leads a non-profit.
30. Lindahl JR et al. The varieties of contemplative experience. PLOS ONE 2017 — US; NCCIH, the Bial Foundation (described by the authors as a commercial source), the 1440 Foundation and the Mind and Life Institute.
31. Baer R et al. Doing no harm in mindfulness-based programs. Clin Psychol Rev 2019 — US/UK; three of four authors at the University of Oxford, including the Oxford Mindfulness Centre's director; Wellcome grant 104908.
32. Gu J et al. How do MBCT and MBSR improve mental health? Meta-analysis of mediation studies. Clin Psychol Rev 2015 — UK (Sussex Mindfulness Centre); funding not listed in the record.
33. van der Velden AM et al. Mechanisms of change in MBCT for recurrent depression. Clin Psychol Rev 2015 — Denmark/UK; Wellcome grant 104908.
34. Van Dam NT et al. Mind the hype. Perspect Psychol Sci 2018 — US/international; workshops funded by the Mind and Life Institute.
35. Coronado-Montoya S et al. Reporting of positive results in mindfulness trials. PLOS ONE 2016 — Canada/US; no funding; no competing interests.
36. Rycroft-Malone J et al. Accessibility and implementation of MBCT in UK NHS services. BMJ Open 2019 (full text) — UK; NIHR HS&DR and Wellcome; authors include directors of mindfulness training centres.
37. Huberty J et al. Calm app for college student stress. JMIR Mhealth Uhealth 2019 — US; lead author is Calm's Director of Science, disclosed in the paper.
38. Taylor H et al. Headspace for health care worker stress. JMIR Mhealth Uhealth 2022 — UK; doctoral studentship funded by Headspace.
39. UMass Memorial Health Center for Mindfulness, MBSR, MBCT and tuition pages — US course provider (seller).
40. Oxford Mindfulness Foundation, personal learning courses — UK charity and course provider.
41. Brown University School of Public Health. MBSR and health insurance coverage (2024) — US university news.
42. The Mindfulness Initiative. Mindful Nation UK report (2015) — UK advocacy charity; secretariat to the Mindfulness All-Party Parliamentary Group.
43. TechCrunch. Calm raises $75M at $2B valuation (8 December 2020) — US technology press.
44. pharmaphorum. Headspace and Ginger finalise $3bn merger (2021) — UK health-industry press.
45. HLTH. Sword to acquire Headspace in deal worth up to $300M (September 2026) — US health-industry events and news company.
46. NIHR. About us; Wellcome. Investments; PCORI. About — funders' own descriptions of how they are funded.

Educational research reviewed 6 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.